School of Medicine & Surgery, Nanomedicine Center NANOMIB, Milan Center for Neuroscience (NeuroMi), University of Milano-Bicocca, Via Cadore 48, 20900 Monza (MB), Italy.
Nanomedicine (Lond). 2018 Mar;13(6):585-594. doi: 10.2217/nnm-2017-0317. Epub 2018 Jan 29.
To investigate if and how the ability of liposomes, previously designed for Alzheimer's therapy, to reach the brain changes in aging/pathological conditions with respect to the healthy state.
Biodistribution and pharmacokinetics of liposomes in young or aged healthy mice and in an Alzheimer's mouse model were measured by radiochemical techniques. The expression of brain receptors and structural proteins was evaluated by Western blot.
At equal blood levels, the amount and integrity of liposomes in the brain were dramatically lower in Alzheimer's or aged mice, with respect to young animals. These differences are likely attributable to molecular alterations in the brain vasculature.
Brain alterations in pathology or aging should be considered in the design of drug delivery systems for brain targeting.
研究先前设计用于治疗阿尔茨海默病的脂质体进入大脑的能力是否以及如何在衰老/病理条件下发生变化，与健康状态相比。
通过放射性化学技术测量脂质体在年轻或年老健康小鼠以及阿尔茨海默病小鼠模型中的分布和药代动力学。通过 Western blot 评估脑受体和结构蛋白的表达。
在相等的血液水平下，与年轻动物相比，阿尔茨海默病或年老小鼠脑中的脂质体数量和完整性明显降低。这些差异可能归因于脑血管的分子改变。
在设计用于脑靶向的药物递送系统时，应考虑病理或衰老状态下的大脑改变。
Zotero 插件